Conference Coverage

Canagliflozin falls short for primary CV prevention in T2DM

Publish date: February 2, 2018

 

REPORTING FROM THE AHA SCIENTIFIC SESSIONS

SOURCE: Mahaffey KW et al. AHA Scientific Sessions.

Pages

Recommended Reading

Type 2 diabetes remitted with low-calorie diet
MDedge Cardiology
ADA guidelines embrace heart health
MDedge Cardiology
Link between glucose control and CVD risk: It’s complicated
MDedge Cardiology
Ertugliflozin gets FDA thumbs-up for glucose control
MDedge Cardiology
Shedding light on shift work’s influence on cardiometabolic risk
MDedge Cardiology
Bariatric surgery comes with some risk of complications
MDedge Cardiology
Gastric bypass T2D benefit can fade over time
MDedge Cardiology
New hematologic, cardiovascular system link may have therapeutic implications
MDedge Cardiology
How to prioritize CVD reduction in type 2 diabetes
MDedge Cardiology
Learn ‘four Ds’ approach to heart failure in diabetes
MDedge Cardiology